U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312305) titled 'Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis' on Dec. 16, 2025.
Brief Summary: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis. Antifibrotic therapy can slow the progression of the disease and reduce mortality, but the life expectancy is less than 7-10 years in the vast majority of patients with IPF. There are no studies in the literature that have evaluated the presence of small airway disease in patients with IPF prior to the initiation of ph...